How to use Prostate-Specific Membrane Antigen-Positron Emission Tomography/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent Webcast (2024)

The learners will understand the following critical clinical aspects with regard to the clinical application of prostate-specific membrane antigen (PSMA) PET/CT; scanning mode of action of PSMA PET/CT; pitfalls of PSMA PET/CT; diagnostic accuracy depending on PSA, PSA double time, prostate cancer histology; application of PSMA PET/CT to identify patients with intrapelvic nodal relapse who will benefit from local therapy such as salvage lymphadenectomy or stereotactic radiation therapy; application of PSMA PET/CT to identify patients with organ-confined radiorecurrent local relapse of prostate cancer who might be candidates for radical salvage prostatectomy; application of new PSMA PET/CT-based clinical staging system as a standardized reporting framework.


This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease.
  2. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings.
  3. Apply the findings of PSMA PET/CT for the best individual therapeutic approach.
  4. Identify patients with radiorecurrent organ-confined prostate cancer.
  5. Identify those patients who are candidates for local therapy of oligometastatic disease in relapsing prostate cancer.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Heidenreich, AxelAstellasConsultant or AdvisorCurrent
AmgenConsultant or AdvisorCurrent
BAYERConsultant or AdvisorCurrent
DendreonConsultant or AdvisorCurrent
FerringConsultant or Advisor12/31/2023
IPSENConsultant or AdvisorCurrent
Jansen CilagConsultant or AdvisorCurrent
PfizerMeeting Participant or LecturerCurrent
Sanofi AventisConsultant or Advisor12/31/2024
TakedaMeeting Participant or LecturerCurrent
BMSScientific Study or TrialCurrent
MSDConsultant or AdvisorCurrent
Karnes, Robert JeffreyNo relevant financial relationships to disclose
Kaye, Deborah R.Janssen PharmaceuticalsConsultant or AdvisorCurrent



PDF iconEducation Council Disclosures


PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2024
Expiration Date: May, 2025

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.